TheraRadar
Clinical-Stage Companies / Bavarian Nordic

Bavarian Nordic

Pre-Approval PRO BETA
43
Total Trials
14
Phase 3
16
Phase 2
5
Recruiting
386
Score

Pipeline by Phase

Phase 3
14
Phase 2
16
Phase 1
11

Therapeutic Focus

Smallpox Chikungunya Virus Respiratory Syncytial Virus Infections Cholera Monkeypox (Mpox)

Clinical Trials (43)

NCT07003984 Phase 3 RECRUITING

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

Started: 6/5/2025

NCT07467707 Phase 3 NOT YET RECRUITING

An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults

Started: 5/1/2026

NCT06007183 Phase 3 ACTIVE NOT RECRUITING

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Started: 8/30/2023

NCT05329220 Phase 3 COMPLETED

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Started: 8/30/2022

NCT05349617 Phase 3 COMPLETED

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

Started: 5/12/2022

NCT05238025 Phase 3 TERMINATED

MVA-BN-RSV Vaccine Trial

Started: 4/19/2022

NCT05072080 Phase 3 COMPLETED

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

Started: 9/29/2021

NCT01895855 Phase 3 COMPLETED

Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera

Started: 9/1/2013

NCT02100631 Phase 3 COMPLETED

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

Started: 5/1/2014

NCT02094586 Phase 3 COMPLETED

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Started: 5/1/2014

NCT03699124 Phase 3 COMPLETED

Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

Started: 6/19/2019

NCT01913353 Phase 3 COMPLETED

A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®

Started: 3/1/2015

NCT01322490 Phase 3 COMPLETED

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Started: 11/28/2011

NCT01144637 Phase 3 COMPLETED

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Started: 2/1/2013

NCT07199569 Phase 2 ACTIVE NOT RECRUITING

Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells

Started: 10/27/2025

NCT06549530 Phase 2 ACTIVE NOT RECRUITING

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

Started: 10/21/2024

NCT06899802 Phase 2 ACTIVE NOT RECRUITING

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

Started: 3/10/2025

NCT03992872 Phase 2 COMPLETED

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

Started: 11/20/2019

NCT05077267 Phase 2 COMPLETED

ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects

Started: 8/19/2021

NCT04752644 Phase 2 COMPLETED

Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

Started: 2/22/2021

NCT05065983 Phase 2 COMPLETED

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine

Started: 10/11/2021

NCT03483961 Phase 2 COMPLETED

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Started: 4/18/2018

NCT03595228 Phase 2 COMPLETED

BN Brachyury and Radiation in Chordoma

Started: 10/31/2018

NCT03628716 Phase 2 COMPLETED

CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Started: 9/18/2018

NCT01668537 Phase 2 COMPLETED

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

Started: 3/1/2013

NCT02873286 Phase 2 COMPLETED

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Started: 9/1/2016

NCT02038881 Phase 2 COMPLETED

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Started: 4/28/2014

NCT00686582 Phase 2 COMPLETED

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

Started: 8/1/2008

NCT00857493 Phase 2 COMPLETED

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Started: 6/1/2009

NCT00891007 Phase 2 COMPLETED

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

Started: 6/1/2009

NCT04246671 Phase 1 COMPLETED

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Started: 8/10/2020

NCT01585181 Phase 1 COMPLETED

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

Started: 4/1/2012

NCT04134312 Phase 1 COMPLETED

A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

Started: 1/8/2020

NCT03349983 Phase 1 COMPLETED

Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)

Started: 1/8/2018

NCT04131595 Phase 1 COMPLETED

Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects

Started: 10/7/2019

NCT02840994 Phase 1 COMPLETED

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

Started: 12/1/2016

NCT01152398 Phase 1 COMPLETED

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy

Started: 6/1/2010

NCT00629057 Phase 1 COMPLETED

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer

Started: 3/1/2008

NCT02864628 Phase 1 WITHDRAWN

RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.

Started: 9/1/2016

NCT02419391 Phase 1 COMPLETED

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

Started: 8/1/2015

NCT00623259 Phase 1 COMPLETED

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

Started: 5/1/2008

NCT03220737 Phase 4 COMPLETED

VAXCHORA Pediatric Study to Assess Safety and Immunogenicity

Started: 7/21/2017

NCT03472014 Phase 4 COMPLETED

Special Access Program IMVAMUNE®

Started: 4/22/2010

Drug Candidates

Jynneos MVA-BN (Quail) CHIKV VLP vaccine Placebo MVA-BN MVA-BN-WEV CHIKV VLP vaccine booster Placebo booster TAEK-VAC-HerBy ABNCoV2
Activity Status: Active
Last Trial Started: 5/1/2026
Last Trial Ended: 12/11/2024
Trials (12 months): 3
Completed Trials: 35
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.